GLI1 and skin basal cell carcinoma: Interestingly, when treated with vismodegib, vismodegib-resistant tumors of BCC patients with SMO mutations (D473H, D473G, and W535L) had significantly higher levels of GLI1 compared to vismodegib-sensitive tumors.